Learn about accelerating target-to-lead antibody candidate selection with the Beacon platform in this Antibody Engineering & Therapeutics Digital Week 2019 webinar.
Find out how Genovac is delivering 10-fold more lead candidates against difficult targets.
Find out how the Opto Plasma B Discovery 4.0 workflow can be used to access broad plasma cell diversity, rapidly down-select lead candidates with functional profiling, and sequence and re-express >1,000 functionally characterized antibodies in 1 week.
Learn how we enable lead candidate down-selection in 1 day by performing functional characterization during primary screening. Case studies highlight how our customers are dramatically accelerating development of next-generation antibody therapeutics.